Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | AGER | Q15109 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963814 | 0.77 | GRIK1 (0.44) | CPA1GRIK1GRIK2PPARGPPARA | |
| SCHEMBL7384829 | 0.73 | CYP1A2 (0.65) | CPA1PPARGPPARAMMECYP1A2 | |
| SCHEMBL12493679 | 0.70 | CYP1A2 (0.55) | CPA1PPARGPPARAMMECYP1A2 | |
| SCHEMBL28181738 | 0.69 | CYP1A2 (0.77) | CPA1PPARGPPARAMMECYP1A2 | |
| SCHEMBL16798335 | 0.69 | MME (0.57) | CPA1PPARGPPARAMMECYP1A2 | |
| SCHEMBL7430616 | 0.68 | METAP2 (0.45) | CPA1SMN1; SMN2RAB9APOLBPPARG | |
| SCHEMBL7430623 | 0.68 | METAP2 (0.45) | CPA1SMN1; SMN2RAB9APOLBPPARG | |
| SCHEMBL5378074 | 0.68 | CYP1A2 (0.57) | CPA1PPARGPPARACYP1A2 | |
| SCHEMBL31344410 | 0.68 | CYP1A2 (0.52) | CPA1PPARGPPARAMMECYP1A2 | |
| SCHEMBL21193997 | 0.68 | CYP1A2 (0.52) | CPA1PPARGPPARAMMECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072907-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | PETER DRAGOVICH S (US) | 2004-04-15 | — | — | US | disclosed |
| US-6649639-B2 | Inhibit or block the biological activity of the picornaviral 3C protease. | DRAGOVICH PETER S (US) | 2003-11-18 | — | — | US | disclosed |
| EP-0975588-B1 | ANTIPICORNAVIRAL COMPOUDS, COMPOSITIONS CONTAINING THEM, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020032237-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | DRAGOVICH PETER S (US) | 2002-03-14 | — | — | US | disclosed |
| US-6331554-B1 | PICORNAVIRUS PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-0975588-A1 | ANTIPICORNAVIRAL COMPOUDS, COMPOSITIONS CONTAINING THEM, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| US-6020371-A | VIRICIDES; PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1998043950-A1 | ANTIPICORNAVIRAL COMPOUDS, COMPOSITIONS CONTAINING THEM, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032237-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | RNASEL, RNASE1, GTF3C3 | CPA1 123/4885BCL2L1 2212/4885MCL1 3114/4885 |
| US-20040072907-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | PCNA, ZC3HAV1, POLR1C | CPA1 1318/4885BCL2L1 1245/4885MCL1 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.